ASSOCIATION BETWEEN RISK FACTORS AND COGNITIVE IMPAIRMENT AMONG TYPE 2 DIABETES MELLITUS PATIENTS

Year 2022, Volume: 7 Issue: 2, 173 - 180, 29.08.2022

Mir Abdul Munif Laxman Verma Malik Faizan Ahmad Anas Ahmad Khan Ankıt Singh

https://doi.org/10.33457/ijhsrp.1025297

Abstract

Background: Diabetes mellitus type 2 is considered as one of the leading causes of illness and mortality through over the globe. Diabetic retinopathy, neuropathy, and nephropathy are all effectively screened on a regular basis. Recent research have shown that cognitive deterioration can occur in patients with diabetes and that it can go unnoticed for a long time, implying that routine screening is necessary.
Methodology: An observational cross sectional study was conducted among 158 patients with complaint of T2DM aged between 60-79 years of age were found with cognitive impairment on the basis of MMSE score in a tertiary care centre. Detailed history along with laboratory and biochemical data were taken from patients after taking written informed consent and approval of Institutional Ethical committee through the pre-structured questionnaire.
Results: Mild cognitive impairment was noted in 88 (55.69%) type 2 diabetes mellitus patients and Normal cognitive function in 70 (44.30%). Those with MCI had higher HbA1c (6.57 ± 1.27 vs. 6.13 ± 1.22), higher FBS (148.34 ± 18.61 vs. 145.25 ± 16.31), PPBS (173.91 ± 42.64 vs. 167.47 ± 38.15) and TNF-α (79.32 ± 8.74 vs. 72.98 ± 6.76), which were statistically significant. The cognitive domains of executive function, naming, attention, language, and memory showed a statistically significant difference between those with Mild cognitive impairment and Normal cognitive function. There were no differences in the mean age, duration of disease, and education level between the groups.
Conclusion: The significant prevalence of Mild cognitive impairment in type 2 diabetes patients emphasizes the value of routine screening of cognitive functions. Further research into the link between cognitive impairment and poor blood glucose control is needed to see if improving blood glucose control can assist in enhancing cognitive functions.

Keywords

Cognitive impairment, Type II diabetes mellitus, MMSE, Risk factors, TNF-α

Supporting Institution

Government Medical COllege, Azamgarh

References

• 1. M. Stumvoll, B. J. Goldstein, and T. W. van Haeften, “Type 2 diabetes: principles of pathogenesis and therapy,” Lancet, vol. 365, no. 9467, pp. 1333–1346, 2005.
• 2. P. Zimmet, K. G. Alberti, and J. Shaw, “Global and societal implications of the diabetes epidemic,” Nature, vol. 414, no. 6865, pp. 782–787, 2001.
• 3. G. J. Biessels, I. J. Deary, and C. M. Ryan, “Cognition and diabetes: a lifespan perspective,” Lancet Neurology, vol. 7, no. 2, pp. 184–190, 2008.
• 4. J. Tang, Y. Pei, and G. Zhou, “When aging-onset diabetes is coming across with Alzheimer disease: comparable pathogenesis and therapy,” Experimental Gerontology, vol. 48, no. 8, pp. 744–750, 2013.
• 5. R. Stewart and D. Liolitsa, “Type 2 diabetes mellitus, cognitive impairment and dementia,” Diabetic Medicine, vol. 16, no. 2, pp. 93–112, 1999. 6. T. Cukierman, H. C. Gerstein, and J. D. Williamson, “Cognitive decline and dementia in diabetes–systematic overview of prospective observational studies,” Diabetologia, vol. 48, no. 12, pp. 2460–2469, 2005.
• 7. R. H. X. Wong, A. Scholey, and P. R. C. Howe, “Assessing premorbid cognitive ability in adults with type 2 diabetes mellitus–a review with implications for future intervention studies,” Current Diabetes Reports, vol. 14, no. 11, p. 547, 2014.
• 8. H. J. Lee, H. I. Seo, H. Y. Cha, Y. J. Yang, S. H. Kwon, and S. J. Yang, “Diabetes and Alzheimer's disease: mechanisms and nutritional aspects,” ClinNutr Res., vol. 7, no. 4, pp. 229– 240, 2018.
• 9. C. Qiu, B. Winblad, and L. Fratiglioni, “The age-dependent relation of blood pressure to cognitive function and dementia,” Lancet Neurology, vol. 4, no. 8, pp. 487–499, 2005.
• 10. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon, “Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study,” Lancet Neurology, vol. 5, no. 3, pp. 228–234, 2006.
• 11. Roy S, Kim N, DesaiA, Komaragiri M, Baxi N, Jassil N, et al. Cognitive function and control of type 2 diabetes mellitus in young adults. N Am J Med Sci 2015;7:220 6.
• 12. Khullar S, Kaur G, Dhillon H, Sharma R, Mehta K, Singh M, et al. The prevalence and predictors of cognitive impairment in type 2 diabetic population of Punjab, India. J Soc Health Diabetes 2017;5:47 53.
• 13. Solanki, R K., Dubey V, Munshi, D. Neurocognitive impairment and comorbid depression in patients of diabetes mellitus. Int J Diabetes DevCtries 2009;29:133 8.
• 14. Cukierman Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: The action to control cardiovascular risk in diabetes memory in diabetes (ACCORD MIND) trial. Diabetes Care 2009;32:221 6.
• 15. Munshi M, Grande L, Hayes M, Ayres D, Suhl E, Capelson R. Cognitive dysfunction is associated with poor diabetes control in older adults. Diabetes Care 2006;29:1794 9.
• 16. Li X, Jia S, Zhou Z, Jin Y, Zhang X, Hou C, et al. The role of Montreal Cognitive Assessment (MoCA) and its memory tasks for detecting mild cognitive impairment. NeurolSci 2018;39:1029 34.
• 17. Luchsinger JA, Palmas W, Teresi JA, Silver S, Kong J, Eimicke JP, et al. Improved diabetes control in the elderly delays global cognitive decline. J Nutr Health Aging 2011;15:445 9.
• 18. Liu XY, Li L, Xiao JQ, He CZ, Lyu XL, Gao L, et al. Cognitive training in older adults with mild cognitive impairment. Biomed Environ Sci 2016;29:356 64.
• 19. Sukontapol C, Kemsen S, Chansirikarn S, Nakawiro D, Kuha O, Taemeeyapradit U. The effectiveness of a cognitive training program in people with mild cognitive impairment: A study in urban community. Asian J Psychiatr 2018;35:61 6.